Opportunities
Active & Upcoming Solicitations
Closed Solicitations
| RPP # | Topic | Description | Submission Due Date |
|---|---|---|---|
| RFI: NMJ MPS Platforms for BoNT Potency Assay | The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to assess the current landscape of human-relevant neuromuscular junction (NMJ) micro-physiological systems (MPS) and their potential application for botulinum neurotoxin (BoNT) detection, potency measurement, and evaluation of medical countermeasure (MCM) neutralizing activity. | 11 May 2026 by 1 p.m. ET | |
| RRPV RPP-26-10-RAPID | Rapid Antibody Production for Immunoassay Diagnostics (RAPID) | The purpose of this RPP is to support advanced research and development of rapid antibody or other protein-based molecular recognition reagents generation platforms to enable timely production of immunoassay-ready reagents to detect pathogens for eventual use in diagnostics. BARDA seeks highly flexible, rapidly adaptable systems capable of generating high-performance binders against pathogens, both known or previously unknown biological threats during public health emergencies. | 13 May 2026 by 1 p.m. ET |
| Coming Soon | New Vaccine Platforms (NVP) | The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing. | TBD |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| Request for Information: PreventARDS (4/1/2026) | Host Directed Therapeutics for the Prevention of Progression to ARDS | 4/15/2026 |
| RRPV RPP-26-07-ASSURE (11/14/2025) | Assay Development for Superior Understanding of Response and Efficacy (ASSURE) | 2/24/2026 |
| New Vaccine Platforms Request for Information (11/26/2025) | New Vaccine Platforms | 1/30/2026 |
| Rapid Antibody Production for Immunoassay Diagnostics (RAPID) Request for Information (10/31/2025) | Rapid Antibody Production | 12/4/2025 |
| RRPV RPP-26-09-AgDx (10/23/2025) | Agnostic Diagnostics | 11/20/2025 |
RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 8/4/2025 |
| RPP-24-07-CentralIEIDLab (5/7/2025) | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | 5/30/2025 |
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | 2/28/2025 |
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | 11/15/2024 |
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 4/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 3/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 3/20/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 1/19/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 1/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 1/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |